Survodutide
Survodutide is a 29-amino-acid peptide developed for weight loss and treatment of MASH.
We have not published an audit on Survodutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Survodutide acts as a dual GLP-1 and glucagon receptor agonist, targeting both receptors simultaneously. [Source: Peptide Dosing Protocols]
Survodutide is a once-weekly injection that activates two receptors at the same time, one that reduces appetite (GLP-1) and one that may help the body burn more calories and reduce liver fat (glucagon), which is why it is being studied for both weight loss and a serious fatty liver disease called MASH.
Reported side effects
The most common side effects of survodutide in trials were nausea, vomiting, diarrhea, and constipation, which were worst during the dose-escalation phase and often improved once the dose leveled off.
Who should avoid it
People who are pregnant or breastfeeding, have a personal or family history of medullary thyroid cancer or MEN 2, have had pancreatitis, have severe gut disease, take insulin or sulfonylureas, are children or teenagers, or have known peptide allergies should avoid survodutide outside of a formal clinical trial.
What gets monitored
Weight, waist size, blood pressure, heart rate, fasting glucose, HbA1c for people with diabetes, and basic liver labs are suggested for monitoring. [Source: Peptide Dosing Protocols]